AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05767437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal drawing-in maneuver exercise
Description: From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
Study NCT05767437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham
Description: Release pain or upper limb mobilization
Study NCT05102734 — intervention group
Intervention type: DRUG
Intervention: Nitroglycerin Topical Product
Description: Topical nitroglycerin solution
Study NCT06526247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength at Home (SAH)
Description: SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
Study NCT06526247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual for IPV
Description: Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
Study NCT05630638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
Study NCT05630638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
Study NCT05473039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seidivid Ferty4
Description: The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
Study NCT05473039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
Study NCT04981717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: SC for a total of 5 administrations
Study NCT06306300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Specialist - Epclusa 400Mg-100Mg Tablet
Description: HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.
Study NCT06306300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non- specialist - Epclusa 400Mg-100Mg Tablet
Description: HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
Study NCT06377488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter
Description: Test Lens
Study NCT05997212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks.
Study NCT05997212 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Sham)
Description: The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed facing away from the skull to avoid an effect.
Study NCT05332132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heracure Device
Description: Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
Study NCT04623008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Episodic Future Thinking
Description: Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
Study NCT06248762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adappt
Description: An app to support parents of children with a NDD
Study NCT06248762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adappt
Description: An app to support parents of children with a NDD
Study NCT04543526 — intervention group
Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
Study NCT06261658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryopreserved Ovarian Tissue Reimplantation
Description: Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Study NCT06065371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
Study NCT06065371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govetican
Description: Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5.
Study NCT05166161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Study NCT06425471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KARL STORZ fetoscope arm
Description: The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
Study NCT05859334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05859334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT05859334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05859334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Undergo OCT
Study NCT04920097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person training for seed placement and APA
Description: In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.
Study NCT04920097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual training for seed placement and APA
Description: Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.
Study NCT04920097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will continue with usual care from oncologist.
Study NCT04920097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-training zoom session for seed placement and APA coaching
Description: Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
Study NCT05782777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
Description: The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
Study NCT05782777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity statin monotherapy (atoravastatin 40mg)
Description: The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
Study NCT06256744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Resistance exercise
Study NCT05385055 — intervention group
Intervention type: OTHER
Intervention: THS use
Description: N/A: No intervention was assigned.
Study NCT05385055 — intervention group
Intervention type: OTHER
Intervention: Cigarette smoking
Description: N/A: No intervention was assigned.
Study NCT05385055 — intervention group
Intervention type: OTHER
Intervention: Smoking abstinence
Description: N/A: No intervention was assigned.
Study NCT06369116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTI HCV Self Test
Description: Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received.
Study NCT05710848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STM-416
Description: STM-416 monotherapy
Study NCT06524908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and dietary calorie restriction
Description: The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
Study NCT04356976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventralex
Description: Repair of hernia using Ventralex patch in sublay position
Study NCT04356976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stratafix
Description: Repair of hernia without mesh. Defect closed with Stratafix suture.
Study NCT05574959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: investigational IOL Model DEN00V
Description: Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
Study NCT05574959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control IOL Model ZCB00/DCB00
Description: Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
Study NCT06363539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION
Description: steroid used for umblical granuloma
Study NCT06363539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: silver nitrate used for treatment
Study NCT05672550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bayesian based dose adjustment of enoxaparin
Description: A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7.
Study NCT05672550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual dose adjustment of enoxaparin
Description: A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
Study NCT05678257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosifloxuridine Nafalbenamide
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion
Study NCT05678257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Intravenous infusion
Study NCT05370443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills education program
Description: The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations.
Study NCT05327972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).
Description: Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
Study NCT05327972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
Study NCT06537674 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
Description: Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
Study NCT05593627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate 250 MG Oral Tablet
Description: Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
Study NCT05593627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate 500 MG Oral Tablet
Description: Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
Study NCT06219304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal functional training
Description: 40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
Study NCT06219304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Exercises aimed at improving balance and mobility
Study NCT05411705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
Study NCT05411705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: Non-rhTPO treatment
Study NCT05635695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Museum visit
Description: People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
Study NCT05635695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural pathways App
Description: Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
Study NCT05294510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAR Sick Child Job Aid
Description: The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
Study NCT06420024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: See: https://link.springer.com/chapter/10.1007/0-306-48581-8_1
Study NCT04845763 — intervention group
Intervention type: OTHER
Intervention: FQoR-15 questionnaire
Description: The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
Study NCT05814744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
Study NCT05814744 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: bupivacaine 0.25%
Description: patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
Study NCT05814744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.25%
Description: patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
Study NCT05814744 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thyroidectomy Surgery
Description: surgical removal of all or part of thyroid gland.
Study NCT05814744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy Surgery
Description: surgical removal of all or part of thyroid gland.
Study NCT05814744 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound-guided intermediate Cervical Plexus Block Technique
Description: the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.